

World Journal of AIDS





www.scirp.org/journal/wja/

Journal Editorial Board

ISSN: 2160-8814 (Print), 2160-8822 (Online) http://www.SciRP.org/journal/wja/

Executive Editor-in-Chief

Dr. Jayashree Seema Nandi

Albert Einstein College of Medicine, USA

Editorial Board

Dr. Julianne Bayliss Dr. Fernando Martín Biscione Dr. Christian A. Devaux **Dr. Pere Domingo** Dr. Mohamed G. Elfaki **Prof. Don Mark Estes** Dr. Daniele Focosi Dr. Hezhao Ji Dr. Basak Kayhan **Prof. Mark Stephen Kindy** Prof. Denise M. Korniewicz Prof. Kyu-Sup Lee Dr. Julio Martín-García Prof. Linda D. Moneyham Prof. Basavraj S. Nagoba Dr. Giuseppe Nunnari **Prof. Patricia Price** Prof. Yuhua Ruan Dr. Fausto Titti Dr. Alexander Y. Tsygankov Dr. Shailendra Kumar Verma Dr. Vincent Vieillard **Prof. Chi-Chiang Yang Prof. Chunfu Zheng**

Monash University, Australia Minas Gerais Federal University, Brazil Montpellier University and CNRS, France Autonomous Unversity of Barcelona, Spain King Faisal Specialist Hospital and Research Centre, Saudi Arabia University of Texas, USA Azienda Ospedaliero-Universitaria Pisana, Italy Public Health Agency of Canada, Canada Inonu University, Turkey Medical University of South Carolina, USA University of Miami Miller, USA Pusan National University, South Korea Drexel University, USA The University of Alabama, UK MIMSR Medical College, India University of Catania, Italy University of Western Australia, Australia Chinese Center for Disease Control and Prevention, China National AIDS Center, Italy Temple University, USA Defence Research & Development Establishment, India Centre National de la Recherche Scientifique, France Chung Shan Medical University, Chinese Taipei Chinese Academy of Sciences, China



TABLE OF CONTENTS

Volume 3 Number 3

September 2013

The Motivations and Experiences of Young Women in a Microbicide Trial in the USA and Puerto	Rico
R. Giguere, G. D. Zimet, J. A. Kahn, C. Dolezal, CS. Leu, M. Mabragaña, I. McGowan, A. Carballo-Diéguez	
Graves' Disease as a Late Manifestation of Immune Reconstitution Syndrome	
after Highly Active Antiretroviral Therapy in an HIV-1 Infected Patient	
E. Mingote, A. Urrutia, A. Viteri, C. Faingold, C. Musso	187
Laboratory Profile of HIV-2 and Dual HIV-1/HIV-2 Associated Acquired	
Immunodeficiency Syndrome in Nigeria	
G. N. Odaibo, D. O. Olaleye	
Diagnosis of HIV Delay: Lost Opportunities	
P. Jiménez-Aguilar, A. R. Palacios, G. García-Dominguez, J. Borrallo-Torrejon, E. Vergara-Moragues,	
E. Cruz-Rosales, A. V. de Campos	197
Characterization of Candida Species Isolated from Cases of Lower Respiratory	
Tract Infection among HIV/AIDS Patients in Calabar, Nigeria	
O. M. Ogba, L. N. Abia-Bassey, J. Epoke, B. I. Mandor, G. D. Iwatt	201
Histopathological Analysis about Autopsies from HIV/AIDS Patients—About Two Decades of	
Research Comparing Results before and after Antiretroviral Therapy Advent	
A. D. P. Ruppert, A. de M. Soeiro, M. C. F. de Almeida, V. L. Capelozzi, C. V. Serrano Jr	
Hepatitis E Virus Infection in HIV Positive ART Naïve and Experienced Individuals in Nigeria	
G. N. Odaibo, D. O. Olaleye	216
The Role of Human Herpesvirus 8 Molecular Characterization in the Management of	
HIV Infected Patients Diagnosed with Malignancies Associated with Its Infection	
M. P. Ariel, K. Vivian, B. Orestes, C. Virginia, A. Yoandra, A. Yoan, V. Denis, J. Narciso, C. Iraida, F. Gilberto,	
U. Yaumara, C. Odalys, Á. Alina, U. Hengge	221
Fear of HIV Susceptibility Influencing Burden of Care among Nurses in South-East Nigeria	
E. F. Asuquo, P. Adejumo, J. Etowa, A. Adejumo	231
Treatment Adherence, Quality of Life and Clinical Variables in HIV/AIDS Infection	
A. Reis, M. P. Guerra, L. Lencastre	
Use of Dried Blood Spot to Improve the Diagnosis and Management of HIV	
in Resource-Limited Settings	
C. Adawaye, E. Kamangu, A. M. Moussa, B. Tchoumbou, D. Vaira, M. Moutschen	251
HIV-Related Disability in HIV Hyper-Endemic Countries: A Scoping Review	
J. Hanass-Hancock, I. Regondi, L. van Egeraat, S. Nixon	257
Darunavir Resistance in HIV Infecting Protease Inhibitor-Experienced Mexican Patients	
C. A. Agudelo, L. E. Soto-Ramírez, A. Katime-Zúñiga, L. Cabrera-Ruíz, H. Lara-Sánchez, J. J. Calva	
Dramatic Improvement in Physical Well-Being of Terminal AIDS Patients Following	
Administration of Phytochemicals	
M. de las M. L. Díaz, F. A. C. Jiminian, R. Wernik, W. F. Goldman, G. Borkow	

World Journal of AIDS (WJA)

Journal Information

SUBSCRIPTIONS

World Journal of AIDS (Online at Scientific Research Publishing, www.SciRP.org) is published quarterly by Scientific Research Publishing, Inc., USA.

Subscription rates:

Print: \$59 per issue. To subscribe, please contact Journals Subscriptions Department, E-mail: sub@scirp.org

SERVICES

Advertisements Advertisement Sales Department, E-mail: service@scirp.org

Reprints (minimum quantity 100 copies) Reprints Co-ordinator, Scientific Research Publishing, Inc., USA. E-mail: sub@scirp.org

COPYRIGHT

Copyright©2013 Scientific Research Publishing, Inc.

All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, scanning or otherwise, except as described below, without the permission in writing of the Publisher.

Copying of articles is not permitted except for personal and internal use, to the extent permitted by national copyright law, or under the terms of a license issued by the national Reproduction Rights Organization.

Requests for permission for other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works or for resale, and other enquiries should be addressed to the Publisher.

Statements and opinions expressed in the articles and communications are those of the individual contributors and not the statements and opinion of Scientific Research Publishing, Inc. We assumes no responsibility or liability for any damage or injury to persons or property arising out of the use of any materials, instructions, methods or ideas contained herein. We expressly disclaim any implied warranties of merchantability or fitness for a particular purpose. If expert assistance is required, the services of a competent professional person should be sought.

PRODUCTION INFORMATION

For manuscripts that have been accepted for publication, please contact: E-mail: wja@scirp.org

cur naturally in plants, beside serving as bionutrients [26, 27], possess radical scavenging activities [28], enhance nonspecific immunity [29], down regulate inflammatory diseases [30], promote health and may inhibit disease progression [31-37]. Here we report that the sole administration of Phyto V7, a phytochemical mix, to terminally ill severely symptomatic AIDS patients significantly improved their well-being.

2. Report

The study was conducted with 9 patients (**Table 1**) living at the Dr. Cruz Jiminian Foundation House (hospice), Santo Domingo, Dominican Republic, between June and September of 2001. All patients were previously diagnosed as being HIV-1 positive with very high viral loads (mean \pm standard deviation of 243,816 \pm 176,724 HIV-1 RNA copies/ml; minimum–50,875, maximum–> 500,000). Eight out of the nine patients were scored as C3 and one as C2, according to the United States Centers for Disease Control (CDC) status index. The CD4+ T-cell counts of only 4 patients was known as determined elsewhere (18, 32, 71 and 45 counts/mm³) and no further measurements could be made or were available to the Foundation. Seven out of the 9 patients were antiretroviral naïve patients. Two had previously been treated with antiretrovirals elsewhere, but apparently developed resistance and failed the treatment. They arrived to the Foundation several months after stopping antiretroviral treatment. None were taking antiretroviral treatment while living in the Hospice, as it was not available to the Foundation then. Following the donation of the Phyto V7 in the form of tablets (registered in the Dominican Republic Ministry and in other countries as a food supplement), and following approval by the Ministry of Health of the Dominican Republic, each patients received 5 tablets 3 times a day, each tablet containing 750 mg of PHT.

None of the patients at the commencement of the study could eat or shower alone. Only 2 out of the 9 patients could dress and sit alone and 3 could stand up alone initially (**Figure 1**). However, after 30 to 45 days of Phyto

Table 1. Characteristics of patients at the beginning of the study.

Patient#	Age	Sex	CDC ^a	VL^{b}	CD4 ^c	Flags ^d	Antiretroviral treatment
201	28	F	C3	91826	ND ^e	N^{f} ; L^{g} ; A^{h} ; An^{i} ; C^{l}	Stopped previous to study
202	33	F	C3	181042	18	$N; E^m; Ly^n; M^o; C$	Naive
203	16	М	C3	159850	45	N; E; Ly; C; To ^p	Naive
204	33	F	C3	500000	32	N; L; A; An; D ^q	Naive
205	43	М	C3	334341	ND	E; L; Ly; A; An; C	Naive
206	43	М	C3	59963	ND	N; L; A; D	Naive
207	29	М	C3	500000	71	T; D; C	Stopped previous to study
208	40	М	C3	316446	ND	N; A; Ly:E	Naive
209	44	F	C2	50875	ND	N; L; To ^r	Naïve

^aCenter for Disease Control Score Index; ^bViral load-number of HIV-1 RNA copies/ml; ^cCD4+ T-Cells counts per mm3 blood; ^dClinical major problems; ^eNot determined; ^fNeutropenia; ^gLeukopenia; ^hAnemia; ⁱAnisocytosis; ^lCandidiasis; ^mEosinophilia; ⁿLymphocytosis; ^oMonocytosis; ^pToxoplasmosis; ^qDiarrhea; ^rTonsillitis.



Figure 1. Improvement in the daily day activities of the studied patients.

V7 supplementation, the well-being of the patients improved dramatically, both physically and mentally. Their appetite, mood, capacity to respond to the surroundings and to perform daily activities improved dramatically: all patients could eat, sit down, shower, stand up and dress alone (**Figure 1**).

3. Discussion

Since the establishment of HAART, the prognosis of HIV-1 infected individuals and AIDS patients has improved significantly. However, treatment failure can occur immunologically, virologically, or clinically, significant side effects occur and the salvage treatment options are many times restricted (e.g. due to viral cross-resistance) or are non-available [38]. HAART is also problematic to pregnant women and children [39,40]. In developing countries HAART may be even more harmful because of the high prevalence of ailments such as anemia, malnutrition, and co-infections, such as tuberculosis [41]. Furthermore, since HAART is expensive and needs good infrastructural support and control programs, it is not available to multitude of patients, especially in developing countries [42]. Thus, new, non-expensive, safe, easy to take, alternative or complementary remedies, that can improve the patient's well-being, are very attractive for the treatment of individuals that fail HAART or antiretroviral naïve patients that cannot get antiretroviral therapy. A food supplement, such as the PHT examined in this study, is extremely inexpensive as compared to HAART. PHT are from a natural source. They have been in the market for several years and have no adverse effects. Also, as opposed to antiretrovirals, since they do not affect directly HIV-1, their uptake with low adherence does not result in appearance of drug resistant viruses. Obviously, in order to increase their efficacy high compliance is desired. The regimen used in this study, of 5 pills three times a day is not optimal, as taking 15 pills a day, in addition to usually taking other treatments, is cumbersome to the patients and personnel and may result in low adherence. Better formulations should be developed in the future. Be as it may, it is clear that the administration of the Phyto V7 improved very dramatically the well-being of the patients. Unfortunately, no viral load or CD4+ T-cell counts were taken from the patients after the 3 months PHT supplementation, so it cannot be determined if there was an improvement in the CD4 counts or reduction of viremia as a consequence of the PHT supplementation. Future studies should carefully examine this.

This study, while it was not a controlled study, strongly supports the notion that Phyto V7 supplementation can improve significantly the well-being of terminally ill AIDS patients. Part of their positive effects can be explained as PHT having radical scavenging activities [28], stimulating nonspecific immunity [29], and by down regulating inflammatory responses [30]. We hypothesize that 1) PHT supplementation can also improve significantly the well-being of AIDS patients not necessarily in terminally ill conditions, by improving the capacity of the HIV-1 infected individuals to cope with the viral infection, 2) PHT supplementation may potentially postpone the need to treat HIV-1 infected individuals with HAART, postponing the potential complications associated with this treatment, and 3) HIV-1 infected individuals undergoing HAART and PHT supplementation would have a better prognosis that those undergoing HAART only. This study serves as the impetus to conduct further studies with significantly larger cohorts of HIV-1 infected individuals and AIDS patients, to substantiate our hypotheses.

REFERENCES

- T. J. Barber, A. Hughes, W. W. Dinsmore and A. Phillips, "How Does HIV Impact on Non-AIDS Events in the Era of HAART?" *International Journal of STD AIDS*, Vol. 20, No. 1, 2009, pp. 1-3. doi:10.1258/ijsa.2008.008302
- [2] M. A. Hacker, A. Kaida, R. S. Hogg and F. I. Bastos, "The First Ten Years: Achievements and Challenges of the Brazilian Program of Universal Access to HIV/AIDS Comprehensive Management and Care, 1996-2006," *Cadernos de Saúde Pública*, Vol. 23, No. S3, 2007, pp. S345-S359.
- [3] D. Ogoina *et al.*, "Morbidity and Mortality Patterns of Hospitalised Adult HIV/AIDS Patients in the Era of Highly Active Antiretroviral Therapy: A 4-Year Retrospective Review from Zaria, Northern Nigeria," *AIDS Research and Treatment*, Vol. 2012, No. 2012, 2012, Article ID: 940580.
- [4] O. Keiser *et al.*, "Adverse Events to Antiretrovirals in the Swiss HIV Cohort Study: Effect on Mortality and Treatment Modification," *Antiviral Therapy*, Vol. 12, No. 8, 2007, pp. 1157-1164.
- [5] R. J. Zinn, C. Serrurier, S. Takuva, I. Sanne and C. N. Menezes, "HIV-Associated Lipodystrophy in South Africa: The Impact on the Patient and the Impact on the Plastic Surgeon," *Journal of Plastic, Reconstructive & Aesthetic Surgery*, Vol. 66, No. 6, 2013, pp. 839-844. doi:10.1016/j.bjps.2013.02.032
- [6] J. M. Llibre *et al.*, "The Changing Face of HIV/AIDS in Treated Patients," *Current HIV Research*, Vol. 7, No. 4, 2009, pp. 365-377. <u>doi:10.2174/157016209788680633</u>
- [7] S. Emamzadeh-Fard, S. E. Fard, S. Seyed Alinaghi and K. Paydary, "Adherence to Anti-Retroviral Therapy and Its Determinants in HIV/AIDS Patients: A Review," *Infectious Disorders Drug Targets*, Vol. 12, No. 5, 2012, pp. 346-356. doi:10.2174/187152612804142251
- [8] S. Bautista-Arredondo, T. Dmytraczenko, G. Kombe and S. M. Bertozzi, "Costing of Scaling up HIV/AIDS Treatment in Mexico," *Salud Pública de México*, Vol. 50, No. S4, 2008, pp. S437-S444.
- [9] S. Apanga, D. Punguyire and G. Adjei, "Estimating the

290 Dramatic Improvement in Physical Well-Being of Terminal AIDS Patients Following Administration of Phytochemicals

Cost to Rural Ambulating HIV/AIDS Patients on Highly Active Antiretroviral Therapy (HAART) in Rural Ghana: A Pilot Study," *The Pan African Medical Journal*, Vol. 12, No. 2012, 2012, p. 21.

- [10] E. Naik *et al.*, "Cost of Treatment: The Single Biggest Obstacle to HIV/AIDS Treatment Adherence in Lower-Middle Class Patients in Mumbai, India," *Indian Journal of Sexually Transmitted Diseases*, Vol. 30, No. 1, 2009, pp. 23-27. doi:10.4103/0253-7184.55476
- [11] M. Fantoni *et al.*, "Symptom Profile in Terminally III AIDS Patients," *AIDS Patient Care and STDs*, Vol. 10, No. 3, 1996, pp. 171-173. doi:10.1089/apc.1996.10.171
- [12] M. J. Hommes *et al.*, "Increased Resting Energy Expenditure in Human Immunodeficiency Virus-Infected Men," *Metabolism*, Vol. 39, No. 11, 1990, pp. 1186-1190. <u>doi:10.1016/0026-0495(90)90092-Q</u>
- [13] J. C. Melchior *et al.*, "Resting Energy Expenditure in Human Immunodeficiency Virus-Infected Patients: Comparison between Patients with and without Secondary Infections," *The American Journal of Clinical Nutrition*, Vol. 57, No. 5, 1993, pp. 614-619.
- [14] J. C. Melchior *et al.*, "Resting Energy Expenditure Is Increased in Stable, Malnourished HIV-Infected Patients," *The American Journal of Clinical Nutrition*, Vol. 53, No. 2, 1991, pp. 437-441.
- [15] M. J. Batterham, "Investigating Heterogeneity in Studies of Resting Energy Expenditure in Persons with HIV/ AIDS: A Meta-Analysis," *The American Journal of Clinical Nutrition*, Vol. 81, No. 3, 2005, pp. 702-713.
- [16] World Health Organization, "Nutrient Requirements for People Living with HIV/AIDS: Report of a Technical Consultation," 2003.
- [17] C. R. Loonam and A. Mullen, "Nutrition and the HIV-Associated Lipodystrophy Syndrome," *Nutrition Research Reviews*, Vol. 25, No. 2, 2012, pp. 267-287. doi:10.1017/S0954422411000138
- [18] W. W. Fawzi *et al.*, "A Randomized Trial of Multivitamin Supplements and HIV Disease Progression and Mortality," *The New England Journal of Medicine*, Vol. 351, No. 1, 2004, pp. 23-32. doi:10.1056/NEJMoa040541
- [19] S. Jiamton *et al.*, "A Randomized Trial of the Impact of Multiple Micronutrient Supplementation on Mortality among HIV-Infected Individuals Living in Bangkok," *AIDS*, Vol. 17, No. 17, 2003, pp. 2461-2469. doi:10.1097/00002030-200311210-00008
- [20] J. D. Kaiser *et al.*, "Micronutrient Supplementation Increases CD4 Count in HIV-Infected Individuals on Highly Active Antiretroviral Therapy: A Prospective, Double-Blinded, Placebo-Controlled Trial," *Journal of Acquired Immune Deficiency Syndromes*, Vol. 42, No. 5, 2006, pp. 523-528. doi:10.1097/01.qai.0000230529.25083.42
- [21] K. Kawai *et al.*, "A Randomized Trial to Determine the Optimal Dosage of Multivitamin Supplements to Reduce Adverse Pregnancy Outcomes among HIV-Infected Women in Tanzania," *The American Journal of Clinical Nutrition*, Vol. 91, No. 2, 2010, pp. 391-397. doi:10.3945/ajcn.2009.28483
- [22] R. D. Semba *et al.*, "Micronutrient Supplements and Mortality of HIV-Infected Adults with Pulmonary TB: A

Controlled Clinical Trial," *The International Journal of Tuberculosis and Lung Disease*, Vol. 11, No. 8, 2007, pp. 854-859.

- [23] J. E. Forrester and K. A. Sztam, "Micronutrients in HIV/ AIDS: Is There Evidence to Change the WHO 2003 Recommendations?" *The American Journal of Clinical Nutrition*, Vol. 94, No. 6, 2011, pp. 1683S-1689S. doi:10.3945/ajcn.111.011999
- [24] N. Siegfried, J. H. Irlam, M. E. Visser and N. N. Rollins, "Micronutrient Supplementation in Pregnant Women with HIV Infection," *Cochrane Database of Systematic Reviews*, Vol. 3, No. 2012, 2012, Article ID: CD009755.
- [25] E. E. Lutge, A. Gray and N. Siegfried, "The Medical Use of Cannabis for Reducing Morbidity and Mortality in Patients with HIV/AIDS," *Cochrane Database of Systematic Reviews*, Vol. 4, No. 2013, Article ID: CD005175.
- [26] X. Kong, G. Wu and Y. Yin, "Roles of Phytochemicals in Amino Acid Nutrition," *Frontiers in Bioscience (Scholar Edition*), Vol. 3, No. 2011, 2011, pp. 372-384.
- [27] B. Holst and G. Williamson, "Nutrients and Phytochemicals: From Bioavailability to Bioefficacy beyond Antioxidants," *Current Opinion in Biotechnology*, Vol. 19, No. 2, 2008, pp. 73-82. <u>doi:10.1016/j.copbio.2008.03.003</u>
- [28] X. Wang *et al.*, "Phytochemicals and Biological Studies of Plants from the Genus Balanophora," *Chemistry Central Journal*, Vol. 6, No. 1, 2012, p. 79. doi:10.1186/1752-153X-6-79
- [29] L. Z. Sun, N. L. Currier and S. C. Miller, "The American Coneflower: A Prophylactic Role Involving Nonspecific Immunity," *Journal of Alternative and Complementary Medicine*, Vol. 5, No. 5, 1999, pp. 437-446. doi:10.1089/acm.1999.5.437
- [30] B. B. Aggarwal and S. Shishodia, "Suppression of the Nuclear Factor-KappaB Activation Pathway by Spice-Derived Phytochemicals: Reasoning for Seasoning," *Annals* of the New York Academy of Sciences, Vol. 1030, No. 2004, 2004, pp. 434-441.
- [31] E. G. de Mejia and M. V. Ramirez-Mares, "Ardisia: Health-Promoting Properties and Toxicity of Phytochemicals and Extracts," *Toxicology Mechanisms and Methods*, Vol. 21, No. 9, 2011, pp. 667-674. doi:10.3109/15376516.2011.601355
- [32] B. N. Rao, "Bioactive Phytochemicals in Indian Foods and Their Potential in Health Promotion and Disease Prevention," *Asia Pacific Journal of Clinical Nutrition*, Vol. 12, No. 1, 2003, pp. 9-22.
- [33] D. O. Kennedy and E. L. Wightman, "Herbal Extracts and Phytochemicals: Plant Secondary Metabolites and the Enhancement of Human Brain Function," *Advances in Nutrition*, Vol. 2, No. 1, 2011, pp. 32-50. doi:10.3945/an.110.000117
- [34] G. P. Kumar and F. Khanum, "Neuroprotective Potential of Phytochemicals," *Pharmacognosy Reviews*, Vol. 6, No. 12, 2012, pp. 81-90.
- [35] M. H. Traka and R. F. Mithen, "Plant Science and Human Nutrition: Challenges in Assessing Health-Promoting Properties of Phytochemicals," *Plant Cell*, Vol. 23, No. 7, 2011, pp. 2483-2497. doi:10.1105/tpc.111.087916

Dramatic Improvement in Physical Well-Being of Terminal AIDS Patients Following Administration of Phytochemicals 291

- [36] S. Rajaram, "The Effect of Vegetarian Diet, Plant Foods, and Phytochemicals on Hemostasis and Thrombosis," *The American Journal of Clinical Nutrition*, Vol. 78, No. S3, 2003, pp. 552S-558S.
- [37] G. Bagalkotkar, S. R. Sagineedu, M. S. Saad and J. Stanslas, "Phytochemicals from Phyllanthus Niruri Linn and Their Pharmacological Properties: A Review," *Journal of Pharmacy and Pharmacology*, Vol. 58, No. 12, 2006, pp. 1559-1570. doi:10.1211/jpp.58.12.0001
- [38] A. Imaz, V. Falco and E. Ribera, "Antiretroviral Salvage Therapy for Multiclass Drug-Resistant HIV-1-Infected Patients: From Clinical Trials to Daily Clinical Practice," *AIDS Reviews*, Vol. 13, No. 3, 2011, pp. 180-193.
- [39] J. F. Senise, A. Castelo and M. Martinez, "Current Treatment Strategies, Complications and Considerations for the Use of HIV Antiretroviral Therapy during Pregnan-

cy," AIDS Reviews, Vol. 13, No. 4, 2011, pp. 198-213.

- [40] C. A. Shah, "Adherence to High Activity Antiretrovial Therapy (HAART) in Pediatric Patients Infected with HIV: Issues and Interventions," *Indian Journal of Pediatrics*, Vol. 74, No. 1, 2007, pp. 55-60. doi:10.1007/s12098-007-0028-8
- [41] R. Subbaraman, S. K. Chaguturu, K. H. Mayer, T. P. Flanigan and N. Kumarasamy, "Adverse Effects of Highly Active Antiretroviral Therapy in Developing Countries," *Clinical Infectious Diseases*, Vol. 45, No. 8, 2007, pp. 1093-1101. doi:10.1086/521150
- [42] O. R. Obiako and H. M. Muktar, "Challenges of HIV Treatment in Resource-Poor Countries: A Review," *Nigerian Medical Journal*, Vol. 19, No. 4, 2010, pp. 361-368. doi:10.4314/njm.v19i4.69785





World Journal of AIDS (WJA)

ISSN 2160-8814 (Print) ISSN 2160-8822 (Online) http://www.SciRP.org/journal/wja/

The World Journal of AIDS is an international journal uniquely devoted to HIV/AIDS with an objective to provide the best quality information, research data and education on all aspects of HIV/AIDS that help in better understanding of HIV/AIDS and improve the quality of patient care. The journal aims to foster the exchange of information among all the health care professionals associated with HIV/AIDS. By publishing the most relevant research articles of high quality, within a peer-review process, it aims to provide with most important, relevant and applied research that is helpful to improve patient care.

Executive Editor-in-Chief

Dr. Jayashree Seema Nandi

Albert Einstein College of Medicine, USA

Editorial Board

- Dr. Julianne Bayliss Dr. Fernando Martín Biscione Dr. Christian A. Devaux Dr. Pere Domingo Dr. Mohamed G. Elfaki Prof. Don Mark Estes Dr. Daniele Focosi Dr. Hezhao Ji
- Dr. Basak Kayhan Prof. Mark Stephen Kindy Prof. Denise M. Korniewicz Prof. Kyu-Sup Lee Dr. Julio Martín-García Prof. Linda D. Moneyham Prof. Basavraj S. Nagoba Dr. Giuseppe Nunnari
- Prof. Patricia Price Prof. Yuhua Ruan Dr. Fausto Titti Dr. Alexander Y. Tsygankov Dr. Shailendra Kumar Verma Dr. Vincent Vieillard Prof. Chi-Chiang Yang Prof. Chunfu Zheng

Subject Coverage

The journal publishes original papers including but not limited to the following fields:

- Diagnosis of HIV/AIDS
- Epidemiology of HIV/AIDS
- Opportunistic Infections in HIV/AIDS
- Pathogenicity of HIV/AIDS

- Political Economy of HIV Infection/AIDS
- Prevention of HIV/AIDS
- Treatment of HIV/AIDS
- Virology & Immunology of HIV/AIDS

The journal accepts papers in following categories: Original research articles, Review articles, Clinical studies, Case reports, Research letters and Clinical images related to HIV/AIDS.

Notes for Intending Authors

Submitted papers should not have been previously published nor be currently under consideration for publication elsewhere. Paper submission will be handled electronically through the website. All papers are refereed through a peer review process. For more details about the submissions, please access the website.

Website and E-Mail

http://www.scirp.org/journal/wja E-mail: wja@scirp.org